WO2012076973A2 - Novel salts of dipeptidyl peptidase iv inhibitor - Google Patents

Novel salts of dipeptidyl peptidase iv inhibitor Download PDF

Info

Publication number
WO2012076973A2
WO2012076973A2 PCT/IB2011/002982 IB2011002982W WO2012076973A2 WO 2012076973 A2 WO2012076973 A2 WO 2012076973A2 IB 2011002982 W IB2011002982 W IB 2011002982W WO 2012076973 A2 WO2012076973 A2 WO 2012076973A2
Authority
WO
WIPO (PCT)
Prior art keywords
sitagliptin
crystalline
acid
powder
ray diffraction
Prior art date
Application number
PCT/IB2011/002982
Other languages
French (fr)
Other versions
WO2012076973A3 (en
Inventor
Mohammed Umar Khan
Ranjith Kumar Srinivasan
Vipin Kumar Kaushik
Koilpillai Joseph Prabahar
Meenakshisunderam Sivakumaran
Original Assignee
Aurobindo Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Limited filed Critical Aurobindo Pharma Limited
Publication of WO2012076973A2 publication Critical patent/WO2012076973A2/en
Publication of WO2012076973A3 publication Critical patent/WO2012076973A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to novel pharmaceutically acceptable salts of 7-[(3R)-3- amino-l- oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-[l ,2,4]-triazolo[4,3- a]pyrazine of Formula I,
  • salt represents formate, picolinate, nicotinate, stearate, palmitate and laurate.
  • Sitagliptin chemically known as 7-[(3R)-3-amino-l-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8- tetrahydro-3-(trifluoromethyl)-[l ,2,4]-triazolo[4,3-a]pyrazine of Formula II,
  • JANUVIA phosphate monohydrate in United States under the trade name JANUVIA ® and is indicated to improve glycemic control in patients with type 2 diabetes mellitus.
  • Sitagliptin phosphate is a glucagon-like peptide 1 (GLP-1) metabolism modulator, hypoglycemic agent, and dipeptidyl peptidase IV inhibitor.
  • GLP-1 glucagon-like peptide 1
  • US 6,699,871 discloses class of ⁇ -amino tetrahydrotriazolo[4,3-a]pyrazines that are potent inhibitors of DPP-IV and therefore useful for the treatment of Type 2 diabetes and specifically discloses Sitagliptin and its pharmaceutically acceptable salts.
  • US 7,326,708 discloses crystalline Sitagliptin dihydrogenphosphate monohydrate; US 7,612,072 discloses amorphous Sitagliptin dihydrogenphosphate; US 2006/0287528 and US 2007/021430 discloses the crystalline anhydrous forms of Sitagliptin dihydrogenphosphate.
  • US 2009/0221592 discloses crystalline anhydrous Sitagliptin dodecyl sulfate.
  • US 2008/0227786 discloses crystalline Sitagliptin hydrochloric acid, benzenesufonic acid, p- toluenesulfonic acid, 10-camphorsulfonic acid, tartaric acid salts and hydrates thereof.
  • WO 2009/085990 discloses Sitagliptin salts such as anhydrous crystalline dihydrogen phosphate Form A, sulfuric acid, hydrobromic acid, methane sulfonic acid, acetic acid, benzoic acid, oxalic acid, succinic acid, mandelic acid, fumaric acid and lactic acid.
  • WO 2010/000469 discloses Sitagliptin malate, glycolate, citrate, maleate salts.
  • WO 2010/012781 discloses crystalline Sitagliptin galactarate Form I, hemi-L-malate Form I, D- gluconate Form I, thiocyanate Form I, L-aspartate Form I, ethanedisulfonate Form 1, pyrroglutamate Form I, glutarate Form I, acetate Form I, citrate amorphous form, hemicitrate amorphous form, glycolate amorphous form, malate amorphous form.
  • WO 2010/092090 discloses Sitagliptin salts, such as D- & L-glucuronic acid, D- & L-lactic acid, D- & L-mandelic acid, ethanesulfonic acid, capric acid, benzoic acid, hippuric acid, trans- cinnamic acid, malonic acid, l-hydroxy-2-naphthoIic acid, crotonic acid, ascorbic acid.
  • Sitagliptin salts such as D- & L-glucuronic acid, D- & L-lactic acid, D- & L-mandelic acid, ethanesulfonic acid, capric acid, benzoic acid, hippuric acid, trans- cinnamic acid, malonic acid, l-hydroxy-2-naphthoIic acid, crotonic acid, ascorbic acid.
  • Sitagliptin salts such as sulfate & its isopropanol solvate, quinate, (+)-dibenzoyltartrate and orotate.
  • 1P.COM Journal, IPCOM000200626 D discloses novel salts of Sitagliptin with acids such as cinnamic, (phenylthio)acetic, caffeic, crotonic, nitric, hydroiodic, malonic, hippuric, 4-hydroxybenzoic acid.
  • Salts often improve physical and biological characteristics of mother compounds without modifying primary pharmacological activity, based on mechanism of action.
  • Different salt forms of the same pharmaceutically active moiety differ in their physical properties such as melting point, solubility etc. These properties may appreciably influence pharmaceutical properties such as dissolution rate, bioavailability.
  • Discovery of new polymorphic forms and solvates of a pharmaceutical product can provide materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms.
  • New polymorphic forms and solvates of a pharmaceutically useful compound or salts thereof can also provide an opportunity to improve the performance characteristics of a pharmaceutical product.
  • New salts of Sitagliptin that may have advantageous physico-chemical and biokinetic properties such as suitable solubility in neutral, acidic or alkaline water medium, solubility in technologically important organic solvents, water/lipid partition coefficient, electrochargeability, thermal stability, water and oxygen inertness, hygroscopicity, crystal shape, particle size and surface, dissolution profile, compatibility with excipients and combined active ingredients or special properties for final dosage form design.
  • the objective of the present invention is to provide novel pharmaceutically acceptable salts of Sitagliptin or solvates or hydrates thereof, having improved physical and chemical properties.
  • FIG. 10 Powder X-ray Diffraction (PXRD) of crystalline Sitagliptin laurate.
  • Figure 1 Powder X-ray Diffraction (PXRD) of amorphous Sitagliptin nicotinate.
  • the present invention relates to novel salts of Sitagliptin of Formula I or solvates or hydrates thereof,
  • salt represents formate, picolinate, nicotinate, stearate, palmitate and laurate.
  • present invention also relates to novel salts of Sitagliptin or solvates or hydrates thereof, which are crystalline.
  • present invention also relates to novel salts of Sitagliptin or solvates or hydrates thereof, which are amorphous.
  • present invention also relates to the amorphous Sitagliptin nitrate salt having the PXRD as per figure 3 and crystalline Sitagliptin nitrate salt having the PXRD as per figure 4.
  • present invention also relates to the Sitagliptin cinnamate hemihydrate having the PXRD as per figure 1.
  • present invention also relates to a process for the preparation of novel crystalline salts of Sitagliptin selected from formate, picolinate, nicotinate, stearate, palmitate, nitrate and laurate.
  • present invention also relates to a process for the preparation of novel amorphous salts of Sitagliptin selected from formate, picolinate, nicotinate, stearate, nitrate, palmitate and laurate.
  • present invention also relates to a process for the preparation of Sitagliptin cinnamate hemihydrate.
  • the present invention relates to novel salts of Sitagliptin of formula I or solvates or hydrates thereof, wherein salt represents formate, picolinate, nicotinate, stearate, palmitate and laurate.
  • present invention relates to the crystalline Sitagliptin formate having powder X- ray diffraction °2 ⁇ values ( ⁇ 0.2) at 14.95, 15.88, 19.32, 19.71 , 26.24.
  • the crystalline Sitagliptin formate is further characterised by PXRD having °2 ⁇ values ( ⁇ 0.2) at 6.27, 7.80, 9.84, 12.53, 14.57, 16.62, 18.33, 20.32, 22.47, 23.47, 24.13, 24.87, 26.99, 29.18, 30.37, 31.00, 34.31, 34.99, 36.98.
  • Another aspect of the present invention relates to the amorphous form of Sitagliptin formate.
  • present invention relates to the crystalline Sitagliptin cinnamate or solvates or hydrates thereof.
  • present invention provides a crystalline Sitagliptin cinnamate hemihydrate having powder X-ray diffraction °20 values ( ⁇ 0.2) at 5.96, 18.51, 19.63, 22.62, 23.71.
  • the crystalline Sitagliptin cinnamate is further characterized by PXRD having °2 ⁇ values ( ⁇ 0.2) at 6.49, 10.01, 1 1.82, 13.04, 14.93, 15.73, 16.41, 17.63, 20.70, 21.44, 23.71, 25.14, 25.76, 26.30, 27.30, 28.83, 31.71, 33.19, 34.73, 36.07, 38.12.
  • Another aspect of the present invention relates to the amorphous form of Sitagliptin cinnamate. Another aspect of the present invention relates to the amorphous form of Sitagliptin nitrate. In another aspect, present invention relates to the crystalline form of Sitagliptin nitrate (herein after referred as Form II) having powder X-ray diffraction °2 ⁇ values ( ⁇ 0.2) at 17.20, 18.48, 22.30, 23.42, 25.60.
  • the crystalline form of Sitagliptin nitrate is further characterized by PXRD having °2 ⁇ values ( ⁇ 0.2) at 7.36, 9.19, 10.84, 13.74, 14.48, 15.23, 17.00, 17.76, 20.78, 21.32, 24.27, 25.9, 26.67, 27.56, 27.93, 28.82, 29.92.
  • present invention relates to the crystalline Sitagliptin picolinate or solvates or hydrates thereof.
  • present invention relates to crystalline Sitagliptin picolinate having powder X- ray diffraction °2 ⁇ values ( ⁇ 0.2) at 14.76, 16.72, 22.93, 26.51, 26.85.
  • the crystalline Sitagliptin picolinate is further characterized by PXRD having °20 values ( ⁇ 0.2) at 10.36, 13.63, 14.27, 15.83, 17.81 , 18.99, 19.41, 20.57, 20.85, 22.17, 24.43, 27.24, 28.76, 29.99, 30.55, 31.06, 31.85, 33.72, 34.63, 35.40, 36.59, 37.62, 38.47.
  • Another aspect of the present invention relates to the amorphous form of Sitagliptin picolinate.
  • present invention relates to the crystalline Sitagliptin nicotinate or solvates or hydrates thereof.
  • crystalline Sitagliptin nicotinate having powder X-ray diffraction °20 values ( ⁇ 0.2) at 15.31 , 16.73, 18.96, 22.57, 26.94.
  • the crystalline Sitagliptin nicotinate is further characterised by PXRD having °2 ⁇ values ( ⁇ 0.2) at 3.88, 5.49, 5.89, 10.40, 14.82, 16.26, 17.38, 18.04, 19.46, 19.90, 21.1 1, 21.87, 23.01, 23.40, 23.71, 24.26, 24.63, 25.00, 25.9327.64, 29.93, 30.66, 31.27, 33.92.
  • Another aspect of the present invention relates to the amorphous form of Sitagliptin nicotinate.
  • present invention relates to the crystalline Sitagliptin stearate or solvates or hydrates thereof.
  • present invention relates to the crystalline Sitagliptin stearate having powder X- ray diffraction °2 ⁇ values ( ⁇ 0.2) at 18.99, 19.41, 20.57, 22.93, 24.43.
  • the crystalline Sitagliptin stearate is further characterized by PXRD having °2 ⁇ values ( ⁇ 0.2) at 10.36, 13.63, 14.27, 14.76, 15.83, 16.72, 17.81 , 20.85, 22.17 ° , 26.51, 26.85, 27.24, 28.76, 29.99, 30.55, 31.06, 31.85, 33.72, 34.63, 35.40, 36.59, 37.62, 38.47.
  • Another aspect of the present invention relates to the amorphous form of Sitagliptin stearate.
  • present invention relates to the crystalline Sitagliptin palmitate or solvates or hydrates thereof.
  • crystalline Sitagliptin palmitate having powder X-ray diffraction °20 values ( ⁇ 0.2) at 19.46, 19.90, 21.1 1 , 23.40, 24.26.
  • the crystalline Sitagliptin palimitate is further characterised by PXRD having °20 values ( ⁇ 0.2) at 3.88, 5.49, 5.89, 10.40, 14.82, 15.31 , 16.26, 16.73, 17.38, 18.04, 18.96, 21.87, 22.57, 23.01 , 23.71, 24.63, 25.00, 25.93, 26.94, 27.64, 29.93, 30.66, 31.27, 33.92. ,
  • Another aspect of the present invention relates to the amorphous form of Sitagliptin palmitate.
  • present invention relates to the crystalline Sitagliptin laurate or solvates or hydrates thereof.
  • Another aspect of the present invention also relates to a crystalline Sitagliptin laurate having powder X-ray diffraction °20 values ( ⁇ 0.2) at 15.80, 18.90, 21.62, 23.90, 24.59.
  • the crystalline Sitagliptin laurate is further characterised by PXRD having °2 ⁇ values ( ⁇ 0.2) at 7.08, 7.29, 12.24, 12.47, 14.15, 14.38, 14.63, 16.24 19.24, 20,13, 22.01, 25.57, 25.83, 26.22, 26.57, 28.49, 29.19, 29.93, 30.99, 31.81, 32.72, 33.01, 34.17, 35.70, 36.48, 38.40.
  • Another aspect of the present invention relates to the amorphous form of Sitagliptin laurate.
  • Another aspect of the present invention relates to a process for the preparation of novel salts of Sitagliptin, which comprises:
  • Sitagliptin base
  • pharmaceutically acceptable acid selected from the group consisting of formic acid, picolinic acid, nicotinic acid, stearic acid, palmitic acid and lauric acid
  • the mixture is prepared by dissolving Sitagliptin base in a solvent selected from water, alcohols, esters, ethers, hydrocarbons, or mixture thereof at temperature in the range of 25 to 100°C and more preferably at 25 to 80°C.
  • a solvent selected from water, alcohols, esters, ethers, hydrocarbons, or mixture thereof at temperature in the range of 25 to 100°C and more preferably at 25 to 80°C.
  • Another aspect of the present invention relates to a process for the preparation of novel amorphous salts of Sitagliptin, which comprises:
  • solvent is selected from water, alcohols or mixtures thereof.
  • the alcohols are pereferably selected from straight chain or branched Ci-C 8 alcohols such as methanol, ethanol, propanol, butanol, isopropanol, isoamyl alcohols and mixtures thereof.
  • Another aspect of the present invention relates to a process for the preparation of Sitagliptin cinnamate hemihydrate, which comprises:
  • solvent is selected from isopropyl alcohol, toluene, ethyl acetate etc.
  • Another aspect of the present invention relates to a process for the preparation of crystalline Form II of Sitagliptin nitrate, which comprises:
  • solvent is water or isopropyl alcohol or mixture thereof.
  • the X-ray powder diffractogram is obtained using Seifert, XRD, 3003 TT systems.
  • the X-ray generator was operated at 40 kv and 30 mA, using the Kal radiation source. It is scanned in the diffraction range of 4° to 40° 20 at a scan rate of 0.02° 20 per second.
  • Formic acid (1.13g, 0.0245 moles) was added to preheated solution of Sitagliptin base (lOg, 0.0245mole) in 150 ml of isopropyl alcohol at 65-70°C. Thereafter, the contents was heated to 75- 80°C and stirred at this temperature for 1 hr. Obtained solution was cooled to 25-30°C and thereafter, precipitated product was stirred further for ⁇ 20h at this temperature. Product was filtered, washed with isopropyl alcohol (2 10ml, 25-30°C) and dried at 55-65°C under reduced pressure (10-50 mm Hg).
  • Formic acid (0.60g, 0.0130 moles) was added to preheated solution of Sitagliptin base (5g, 0.0123mole) in 75 ml of toluene at 75-80°C. Obtained solution was cooled to 25-30°C and thereafter, precipitated product was stirred further for ⁇ 15h at this temperature. Product was filtered, washed with toluene (2x10ml, 25-30°C) and dried at 55-65°C under reduced pressure (10- 50 mm Hg).
  • Sitagliptin formate (lOg) was suspended in acetone (50ml) and stirred at 25-30°C to obtain a solution. To this solution, isopropyl ether (200ml) was added slowly during 30min. Obtained slurry was stirred at 25-30°C for ⁇ 16hr. Product was filtered, washed with isopropyl ether (2x10ml, 25-30°C) and dried at 55-65°C under reduced pressure (10-50 mm Hg).
  • Sitagliptin formate (l Og) was suspended in ethanol (absolute alcohol, 50ml) at 25-30°C. Obtained solution was heated to 45-50°C to obtain a solution. To this solution, cyclohexane (100ml) was added slowly during 30min. Obtained slurry was stirred at 25-30°C for ⁇ 16hr. Product was filtered, washed with cyclohexane (2x10ml, 25-30°C) and dried at 55-65°C under reduced pressure (10-50 mm Hg).
  • Cinnamic acid 22.25g, 0.1503 moles was added to preheated solution of Sitagliptin base (60g, 0.1474mole) in 840 ml of 2%v/v aqueous isopropyl alcohol at 65-70°C. Thereafter, the contents were heated to 70-75°C and stirred at this temperature for lh. Obtained solution was cooled to 25- 30°C and thereafter, stirred further for ⁇ 20h at this temperature. The precipitated product was filtered, washed with isopropyl alcohol (2x60ml, 25-30°C) and dried at 55-60°C under reduced pressure (10-50 mm Hg).
  • Cinnamic acid (3.63g, 0.0245 moles) was added to preheated solution of Sitagliptin base (lOg, 0.0245mole) in 150 ml of toluene at 70-75°C. Thereafter, the contents were maintained at 70-75°C and stirred at this temperature for lh. Obtained solution was cooled to 25-30°C and thereafter, stirred further for ⁇ 15hr at this temperature to obtain a product. It was filtered, washed with toluene (2x10ml, 25-30°C) and dried at 55-60°C under reduced pressure (10-50 mm Hg).
  • Cinnamic acid (3.63g, 0.0245 moles) was added to a solution of Sitagliptin base (lOg, 0.0245mole) in 150 ml of ethyl acetate at 25-30°C. Thereafter, the contents were maintained at 25- 30°C for ⁇ 15hr. The solid was filtered, washed with ethyl acetate (2x10ml, 25-30°C) and dried at 55-60°C under reduced pressure (10-50 mm Hg).
  • Sitagliptin cinnamate (lOg) was suspended in ethyl acetate (100ml) at 25-30°C. The slurry was heated to 75-77°C to obtain a clear solution. This solution was cooled to 25-30°C and stirred further for ⁇ 15hr at this temperature. The crystallized product was filtered, washed with ethyl acetate (2x10ml, 25-30°C) and dried at 55-60°C under reduced pressure (10-50 mm Hg).
  • Crystalline Sitagliptin cinnamate hemihydrate (5g) was dissolved in 650 ml of DM water at 25- 30°C. Thereafter, the contents were filtered and obtained filtrate was lyophilized to obtain amorphous Sitagliptin cinnamate, which is hygroscopic in nature.
  • Crystalline Sitagliptin formate (5g) was dissolved in 15 ml of DM water at 25-30°C. Thereafter, the contents were filtered and obtained filtrate was lyophilized to obtain amorphous Sitagliptin formate, which is hygroscopic in nature.
  • Nicotinic acid (1.51g, 0.0122 moles) was added to preheated solution of Sitagliptin base (5g, 0.0245mole) in 75 ml of isopropyl alcohol at 65-70°C. Thereafter, the contents were heated to 70- 75°C and stirred at this temperature for lh. Obtained solution was concentrated at 40-45°C under reduced pressure to distill ⁇ 60 of isopropyl alcohol and cyclohexane (100ml) was added. Thereafter, precipitated product was stirred further for 5h at 25-30°C. Product was filtered, washed with cyclohexane (2x10ml, 25-30°C) and dried at 50-60°C under reduced pressure (10-50 mm Hg).
  • Picolinic acid (1.5 lg, 0. 0.0122 moles) was added to preheated solution of Sitagliptin base (5g, 0.0122mole) in 75 ml of isopropyl alcohol at 65-70°C. Thereafter, the contents were heated to 70- 75°C and stirred at this temperature for l h. Obtained solution was cooled to 25-30°C and thereafter, precipitated product was stirred further for ⁇ 20h at this temperature. Product was filtered, washed with isopropyl alcohol (2x5ml, 25-30°C) and dried at 50-60°C under reduced pressure (10-50 mm Hg).
  • Nitric acid 50%w/w, 2.84g consult 0.0270 moles was added to preheated solution of Sitagliptin base (l Og, 0.0245mole) in 100 ml of isopropyl alcohol at 50-60°C and contents were stirred at this temperature for 1 hr. Obtained solution was cooled to 25-30°C and thereafter, precipitated product was stirred further for ⁇ 2h at 25-30°C. Product was filtered, washed with isopropyl alcohol (2x10ml, 25-30°C) and dried at 45-50°C under reduced pressure (-20 mm Hg).
  • Nitric acid 50%w/w, 2.58g, 0.024 moles was added to a suspension of Sitagliptin base (lOg, 0.0245mole) in 50 ml of DM water at 25-35°C.
  • Isopropyl alcohol (10ml) was added and contents were stirred at this temperature for 1 hr.
  • the resulting slurry mass was further cooled to 5-10°C and stirred further for ⁇ l h at the same temperature.
  • Product was filtered, washed with precooled DM water (2x10ml, 5-10°C) and dried at 45-50°C under reduced pressure (-20 mm Hg).
  • Crystalline Sitagliptin nitrate (5g) was dissolved in 50 ml of DM water at 25-30°C. Thereafter, the contents were filtered and the filtrate was lyophilized to obtain amorphous Sitagliptin nitrate, which is hygroscopic in nature.

Abstract

The present invention relates to novel pharmaceutically acceptable salts of 7-[(3R)-3- amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-[1,2,-4]-triazolo [4,3-a]pyrazine of Formula (I), or solvates or hydrates thereof.

Description

NOVEL SALTS OF DIPEPTIDYL PEPTIDASE IV INHIBITOR FIELD OF THE INVENTION
The present invention relates to novel pharmaceutically acceptable salts of 7-[(3R)-3- amino-l- oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-[l ,2,4]-triazolo[4,3- a]pyrazine of Formula I,
Figure imgf000002_0001
or solvates or hydrates thereof.
wherein salt represents formate, picolinate, nicotinate, stearate, palmitate and laurate.
BACKGROUND OF THE INVENTION
Sitagliptin, chemically known as 7-[(3R)-3-amino-l-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8- tetrahydro-3-(trifluoromethyl)-[l ,2,4]-triazolo[4,3-a]pyrazine of Formula II,
Figure imgf000002_0002
is marketed in the form of a phosphate monohydrate in United States under the trade name JANUVIA® and is indicated to improve glycemic control in patients with type 2 diabetes mellitus.
Sitagliptin phosphate is a glucagon-like peptide 1 (GLP-1) metabolism modulator, hypoglycemic agent, and dipeptidyl peptidase IV inhibitor. US 6,699,871 discloses class of β-amino tetrahydrotriazolo[4,3-a]pyrazines that are potent inhibitors of DPP-IV and therefore useful for the treatment of Type 2 diabetes and specifically discloses Sitagliptin and its pharmaceutically acceptable salts.
US 7,326,708 discloses crystalline Sitagliptin dihydrogenphosphate monohydrate; US 7,612,072 discloses amorphous Sitagliptin dihydrogenphosphate; US 2006/0287528 and US 2007/021430 discloses the crystalline anhydrous forms of Sitagliptin dihydrogenphosphate.
US 2009/0221592 discloses crystalline anhydrous Sitagliptin dodecyl sulfate.
US 2008/0227786 discloses crystalline Sitagliptin hydrochloric acid, benzenesufonic acid, p- toluenesulfonic acid, 10-camphorsulfonic acid, tartaric acid salts and hydrates thereof.
WO 2009/085990 discloses Sitagliptin salts such as anhydrous crystalline dihydrogen phosphate Form A, sulfuric acid, hydrobromic acid, methane sulfonic acid, acetic acid, benzoic acid, oxalic acid, succinic acid, mandelic acid, fumaric acid and lactic acid.
WO 2010/000469 discloses Sitagliptin malate, glycolate, citrate, maleate salts.
WO 2010/012781 discloses crystalline Sitagliptin galactarate Form I, hemi-L-malate Form I, D- gluconate Form I, thiocyanate Form I, L-aspartate Form I, ethanedisulfonate Form 1, pyrroglutamate Form I, glutarate Form I, acetate Form I, citrate amorphous form, hemicitrate amorphous form, glycolate amorphous form, malate amorphous form.
WO 2010/092090 discloses Sitagliptin salts, such as D- & L-glucuronic acid, D- & L-lactic acid, D- & L-mandelic acid, ethanesulfonic acid, capric acid, benzoic acid, hippuric acid, trans- cinnamic acid, malonic acid, l-hydroxy-2-naphthoIic acid, crotonic acid, ascorbic acid.
US 2010/0249140 discloses Sitagliptin salts, such as sulfate & its isopropanol solvate, quinate, (+)-dibenzoyltartrate and orotate. 1P.COM Journal, IPCOM000200626 D, discloses novel salts of Sitagliptin with acids such as cinnamic, (phenylthio)acetic, caffeic, crotonic, nitric, hydroiodic, malonic, hippuric, 4-hydroxybenzoic acid.
Salts often improve physical and biological characteristics of mother compounds without modifying primary pharmacological activity, based on mechanism of action. Different salt forms of the same pharmaceutically active moiety differ in their physical properties such as melting point, solubility etc. These properties may appreciably influence pharmaceutical properties such as dissolution rate, bioavailability. Discovery of new polymorphic forms and solvates of a pharmaceutical product can provide materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms. New polymorphic forms and solvates of a pharmaceutically useful compound or salts thereof can also provide an opportunity to improve the performance characteristics of a pharmaceutical product. New salts of Sitagliptin that may have advantageous physico-chemical and biokinetic properties such as suitable solubility in neutral, acidic or alkaline water medium, solubility in technologically important organic solvents, water/lipid partition coefficient, electrochargeability, thermal stability, water and oxygen inertness, hygroscopicity, crystal shape, particle size and surface, dissolution profile, compatibility with excipients and combined active ingredients or special properties for final dosage form design.
In view of the foregoing, we have now found novel salts of Sitagliptin and new polymorphic forms of Sitagliptin salts, which are stable and can be used in medical therapy.
OBJECTIVE
The objective of the present invention is to provide novel pharmaceutically acceptable salts of Sitagliptin or solvates or hydrates thereof, having improved physical and chemical properties.
Yet another objective of the present invention is to provide novel salts of Sitagliptin or solvates or hydrates thereof, which are crystalline or amorphous in nature. Yet another objective of the present invention is to provide a safe, productive and easy to handle process for the preparation of salts of Sitagliptin or solvates or hydrates thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 - Powder X-ray Diffraction (PXRD) of crystalline Sitagliptin cinnamate hemi- hydrate.
Figure 2 - Powder X-ray Diffraction (PXRD) of amorphous Sitagliptin cinnamate.
Figure 3 - Powder X-ray Diffraction (PXRD) of amorphous Sitagliptin nitrate.
Figure 4 - Powder X-ray Diffraction (PXRD) of crystalline Sitagliptin nitrate Form-II.
Figure 5 - Powder X-ray Diffraction (PXRD) of crystalline Sitagliptin formate.
Figure 6 - Powder X-ray Diffraction (PXRD) of amorphous Sitagliptin formate.
Figure 7- Powder X-ray Diffraction (PXRD) of crystalline Sitagliptin picolinate.
Figure 8- Powder X-ray Diffraction (PXRD) of crystalline Sitagliptin palmitate.
Figure 9- Powder X-ray Diffraction (PXRD) of crystalline Sitagliptin stearate.
Figure 10- Powder X-ray Diffraction (PXRD) of crystalline Sitagliptin laurate.
Figure 1 1- Powder X-ray Diffraction (PXRD) of amorphous Sitagliptin nicotinate.
Figure 12- Powder X-ray Diffraction (PXRD) of crystalline Sitagliptin nicotinate.
SUMMARY OF THE INVENTION
The present invention relates to novel salts of Sitagliptin of Formula I or solvates or hydrates thereof,
Figure imgf000005_0001
wherein salt represents formate, picolinate, nicotinate, stearate, palmitate and laurate. In another embodiment, present invention also relates to novel salts of Sitagliptin or solvates or hydrates thereof, which are crystalline.
In another embodiment, present invention also relates to novel salts of Sitagliptin or solvates or hydrates thereof, which are amorphous.
In another embodiment, present invention also relates to the amorphous Sitagliptin nitrate salt having the PXRD as per figure 3 and crystalline Sitagliptin nitrate salt having the PXRD as per figure 4.
In another embodiment, present invention also relates to the Sitagliptin cinnamate hemihydrate having the PXRD as per figure 1.
In another embodiment, present invention also relates to a process for the preparation of novel crystalline salts of Sitagliptin selected from formate, picolinate, nicotinate, stearate, palmitate, nitrate and laurate.
In another embodiment, present invention also relates to a process for the preparation of novel amorphous salts of Sitagliptin selected from formate, picolinate, nicotinate, stearate, nitrate, palmitate and laurate.
In another embodiment, present invention also relates to a process for the preparation of Sitagliptin cinnamate hemihydrate.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to novel salts of Sitagliptin of formula I or solvates or hydrates thereof,
Figure imgf000007_0001
wherein salt represents formate, picolinate, nicotinate, stearate, palmitate and laurate.
In another aspect of the present invention also relates to the crystalline Sitagliptin formate or solvates or hydrates thereof.
In another aspect present invention relates to the crystalline Sitagliptin formate having powder X- ray diffraction °2Θ values (±0.2) at 14.95, 15.88, 19.32, 19.71 , 26.24. The crystalline Sitagliptin formate is further characterised by PXRD having °2Θ values (±0.2) at 6.27, 7.80, 9.84, 12.53, 14.57, 16.62, 18.33, 20.32, 22.47, 23.47, 24.13, 24.87, 26.99, 29.18, 30.37, 31.00, 34.31, 34.99, 36.98.
Another aspect of the present invention relates to the amorphous form of Sitagliptin formate.
In another aspect present invention relates to the crystalline Sitagliptin cinnamate or solvates or hydrates thereof.
In another aspect present invention, provides a crystalline Sitagliptin cinnamate hemihydrate having powder X-ray diffraction °20 values (±0.2) at 5.96, 18.51, 19.63, 22.62, 23.71. The crystalline Sitagliptin cinnamate is further characterized by PXRD having °2Θ values (±0.2) at 6.49, 10.01, 1 1.82, 13.04, 14.93, 15.73, 16.41, 17.63, 20.70, 21.44, 23.71, 25.14, 25.76, 26.30, 27.30, 28.83, 31.71, 33.19, 34.73, 36.07, 38.12.
Another aspect of the present invention relates to the amorphous form of Sitagliptin cinnamate. Another aspect of the present invention relates to the amorphous form of Sitagliptin nitrate. In another aspect, present invention relates to the crystalline form of Sitagliptin nitrate (herein after referred as Form II) having powder X-ray diffraction °2Θ values (±0.2) at 17.20, 18.48, 22.30, 23.42, 25.60. The crystalline form of Sitagliptin nitrate is further characterized by PXRD having °2Θ values (±0.2) at 7.36, 9.19, 10.84, 13.74, 14.48, 15.23, 17.00, 17.76, 20.78, 21.32, 24.27, 25.9, 26.67, 27.56, 27.93, 28.82, 29.92.
In another aspect, present invention relates to the crystalline Sitagliptin picolinate or solvates or hydrates thereof.
In another aspect, present invention relates to crystalline Sitagliptin picolinate having powder X- ray diffraction °2Θ values (±0.2) at 14.76, 16.72, 22.93, 26.51, 26.85. The crystalline Sitagliptin picolinate is further characterized by PXRD having °20 values (±0.2) at 10.36, 13.63, 14.27, 15.83, 17.81 , 18.99, 19.41, 20.57, 20.85, 22.17, 24.43, 27.24, 28.76, 29.99, 30.55, 31.06, 31.85, 33.72, 34.63, 35.40, 36.59, 37.62, 38.47.
Another aspect of the present invention relates to the amorphous form of Sitagliptin picolinate.
In another aspect, present invention relates to the crystalline Sitagliptin nicotinate or solvates or hydrates thereof.
In another aspect, present invention, crystalline Sitagliptin nicotinate having powder X-ray diffraction °20 values (±0.2) at 15.31 , 16.73, 18.96, 22.57, 26.94. The crystalline Sitagliptin nicotinate is further characterised by PXRD having °2Θ values (±0.2) at 3.88, 5.49, 5.89, 10.40, 14.82, 16.26, 17.38, 18.04, 19.46, 19.90, 21.1 1, 21.87, 23.01, 23.40, 23.71, 24.26, 24.63, 25.00, 25.9327.64, 29.93, 30.66, 31.27, 33.92.
Another aspect of the present invention relates to the amorphous form of Sitagliptin nicotinate. In another aspect, present invention relates to the crystalline Sitagliptin stearate or solvates or hydrates thereof.
In another aspect, present invention relates to the crystalline Sitagliptin stearate having powder X- ray diffraction °2Θ values (±0.2) at 18.99, 19.41, 20.57, 22.93, 24.43. The crystalline Sitagliptin stearate is further characterized by PXRD having °2Θ values (±0.2) at 10.36, 13.63, 14.27, 14.76, 15.83, 16.72, 17.81 , 20.85, 22.17°, 26.51, 26.85, 27.24, 28.76, 29.99, 30.55, 31.06, 31.85, 33.72, 34.63, 35.40, 36.59, 37.62, 38.47.
Another aspect of the present invention relates to the amorphous form of Sitagliptin stearate.
In another aspect, present invention relates to the crystalline Sitagliptin palmitate or solvates or hydrates thereof.
In another aspect, present invention, crystalline Sitagliptin palmitate having powder X-ray diffraction °20 values (±0.2) at 19.46, 19.90, 21.1 1 , 23.40, 24.26. The crystalline Sitagliptin palimitate is further characterised by PXRD having °20 values (±0.2) at 3.88, 5.49, 5.89, 10.40, 14.82, 15.31 , 16.26, 16.73, 17.38, 18.04, 18.96, 21.87, 22.57, 23.01 , 23.71, 24.63, 25.00, 25.93, 26.94, 27.64, 29.93, 30.66, 31.27, 33.92. ,
Another aspect of the present invention relates to the amorphous form of Sitagliptin palmitate.
In another aspect, present invention relates to the crystalline Sitagliptin laurate or solvates or hydrates thereof.
Another aspect of the present invention also relates to a crystalline Sitagliptin laurate having powder X-ray diffraction °20 values (±0.2) at 15.80, 18.90, 21.62, 23.90, 24.59. The crystalline Sitagliptin laurate is further characterised by PXRD having °2Θ values (±0.2) at 7.08, 7.29, 12.24, 12.47, 14.15, 14.38, 14.63, 16.24 19.24, 20,13, 22.01, 25.57, 25.83, 26.22, 26.57, 28.49, 29.19, 29.93, 30.99, 31.81, 32.72, 33.01, 34.17, 35.70, 36.48, 38.40. Another aspect of the present invention relates to the amorphous form of Sitagliptin laurate.
Another aspect of the present invention relates to a process for the preparation of novel salts of Sitagliptin, which comprises:
a) providing a mixture comprising Sitagliptin (base) and pharmaceutically acceptable acid selected from the group consisting of formic acid, picolinic acid, nicotinic acid, stearic acid, palmitic acid and lauric acid; and
b) isolating the corresponding acid addition salt of Sitagliptin.
wherein said the mixture is prepared by dissolving Sitagliptin base in a solvent selected from water, alcohols, esters, ethers, hydrocarbons, or mixture thereof at temperature in the range of 25 to 100°C and more preferably at 25 to 80°C.
Another aspect of the present invention relates to a process for the preparation of novel amorphous salts of Sitagliptin, which comprises:
a) dissolution of Sitagliptin salts in solvent; and
b) lyophilization.
wherein solvent is selected from water, alcohols or mixtures thereof. The alcohols are pereferably selected from straight chain or branched Ci-C8 alcohols such as methanol, ethanol, propanol, butanol, isopropanol, isoamyl alcohols and mixtures thereof.
Another aspect of the present invention relates to a process for the preparation of Sitagliptin cinnamate hemihydrate, which comprises:
a) addition of cinnamic acid to preheated solution of Sitagliptin base in solvent;
b) heating the solution;
c) cooling to precipitate product; and
d) isolating the product.
wherein solvent is selected from isopropyl alcohol, toluene, ethyl acetate etc. Another aspect of the present invention relates to a process for the preparation of crystalline Form II of Sitagliptin nitrate, which comprises:
a) providing a mixture comprising Sitagliptin base and nitric acid in a solvent; and b) isolating the crystalline Form II of Sitagliptin nitrate
wherein solvent is water or isopropyl alcohol or mixture thereof.
POWDER X-RAY DIFFRACTION (PXRD)
The X-ray powder diffractogram is obtained using Seifert, XRD, 3003 TT systems. The X-ray generator was operated at 40 kv and 30 mA, using the Kal radiation source. It is scanned in the diffraction range of 4° to 40° 20 at a scan rate of 0.02° 20 per second.
The invention is illustrated with the following examples, which are provided by way of illustration only and should not be construed to limit the scope of the invention.
EXAMPLE- 1
PREPARATION OF 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRIFLUOROPHENYL)-BUTYL]- 5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-[l,2,4]-TRIAZOLO-[4^- a]PYRAZINE FORMATE
Formic acid (1.13g, 0.0245 moles) was added to preheated solution of Sitagliptin base (lOg, 0.0245mole) in 150 ml of isopropyl alcohol at 65-70°C. Thereafter, the contents was heated to 75- 80°C and stirred at this temperature for 1 hr. Obtained solution was cooled to 25-30°C and thereafter, precipitated product was stirred further for ~20h at this temperature. Product was filtered, washed with isopropyl alcohol (2 10ml, 25-30°C) and dried at 55-65°C under reduced pressure (10-50 mm Hg).
Yield: 10.70g
Water content: 0.20%w/w (by KF) EXAMPLE-2
PREPARATION OF 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRIFLUOROPHENYL)-BUTYL]- 5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-[l,2,4]-TRIAZOLO-[4,3- a]PYRAZINE FORMATE
Formic acid (0.60g, 0.0130 moles) was added to preheated solution of Sitagliptin base (5g, 0.0123mole) in 75 ml of toluene at 75-80°C. Obtained solution was cooled to 25-30°C and thereafter, precipitated product was stirred further for ~15h at this temperature. Product was filtered, washed with toluene (2x10ml, 25-30°C) and dried at 55-65°C under reduced pressure (10- 50 mm Hg).
Yield: 5.38g
Water content: 0.35%w/w (by KF) EXAMPLE-3
PREPARATION OF 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRIFLUOROPHENYL)-BUTYL]- 5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-[l,2,4]-TRIAZOLO-[4,3- a]PYRAZINE FORMATE
Formic acid (0.60g, 0.0130 moles) was added to solution of Sitagliptin base (5g, 0.0123mole) in 150 ml of ethyl acetate at 25-30°C. Obtained solution was stirred at 25-30°C and thereafter, precipitated product was stirred further for ~15h at this temperature. Product was filtered, washed with ethyl acetate (2x10ml, 25-30°C) and dried at 55-65°C under reduced pressure (10-50 mm Hg).
Yield: 5.18g
Water content: 0.32%w/w (by KF) EXAMPLE-4
CRYSTALLIZATION OF 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRIFLUORO-PHENYL)- BUTYL]-5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-[l,2,4]-TRIAZOLO-[4,3- aJPYRAZINE FORMATE IN ACETONE / ISOPROPYL ETHER
Sitagliptin formate (lOg) was suspended in acetone (50ml) and stirred at 25-30°C to obtain a solution. To this solution, isopropyl ether (200ml) was added slowly during 30min. Obtained slurry was stirred at 25-30°C for ~16hr. Product was filtered, washed with isopropyl ether (2x10ml, 25-30°C) and dried at 55-65°C under reduced pressure (10-50 mm Hg).
Yield: 8.95g
Water content: 0.16%w/w (by KF) EXAMPLE-5
CRYSTALLIZATION OF 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRIFLUORO-PHENYL)- BUTYL]-5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-[l,2,4]-TRIAZOLO-[4,3- a]PYRAZINE FORMATE IN ACETONE / ISOPROPYL ETHER
Sitagliptin formate (l Og) was suspended in ethanol (absolute alcohol, 50ml) at 25-30°C. Obtained solution was heated to 45-50°C to obtain a solution. To this solution, cyclohexane (100ml) was added slowly during 30min. Obtained slurry was stirred at 25-30°C for ~16hr. Product was filtered, washed with cyclohexane (2x10ml, 25-30°C) and dried at 55-65°C under reduced pressure (10-50 mm Hg).
Yield: 9.05g
Water content: 0.14%w/w (by KF) EXAMPLE-6
PREPARATION OF 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRIFLUOROPHENYL)-BUTYL]- 5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-[l,2,4]-TRIAZOLO-[4,3- aJPYRAZINE CINNAMATE HEMIHYDRATE Cinnamic acid (3.63g, 0.0245 moles) was added to preheated solution of Sitagliptin base (lOg, 0.0245mole) in 150 ml of isopropyl alcohol at 65-70°C. Thereafter, the contents were heated to 70-75°C and stirred at this temperature for lh. Obtained solution was cooled to 25-30°C and thereafter, stirred further for ~20h at this temperature to obtain a product. It was filtered, washed with isopropyl alcohol (2x10ml, 25-30°C) and dried at 55-60°C under reduced pressure (10-50 mm Hg).
Yield: 8.33g
Water content: 1.86%w/w (by F) EXAMPLE-7
PREPARATION OF 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRIFLUOROPHENYL)-BUTYLl- 5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-[l,2,4]-TRIAZOLO-[4,3- aJPYRAZINE CINNAMATE HEMIHYDRATE
Cinnamic acid (22.25g, 0.1503 moles) was added to preheated solution of Sitagliptin base (60g, 0.1474mole) in 840 ml of 2%v/v aqueous isopropyl alcohol at 65-70°C. Thereafter, the contents were heated to 70-75°C and stirred at this temperature for lh. Obtained solution was cooled to 25- 30°C and thereafter, stirred further for ~20h at this temperature. The precipitated product was filtered, washed with isopropyl alcohol (2x60ml, 25-30°C) and dried at 55-60°C under reduced pressure (10-50 mm Hg).
Yield: 65.68g
Water content: 1.96%w/w (by KF) EXAMPLE-8
PREPARATION OF 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRIFLUOROPHENYL)-BUTYL]- 5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-[l,2,4]-TRIAZOLO-[4,3- aJPYRAZINE CINNAMATE HEMIHYDRATE
Cinnamic acid (3.63g, 0.0245 moles) was added to preheated solution of Sitagliptin base (lOg, 0.0245mole) in 150 ml of toluene at 70-75°C. Thereafter, the contents were maintained at 70-75°C and stirred at this temperature for lh. Obtained solution was cooled to 25-30°C and thereafter, stirred further for ~15hr at this temperature to obtain a product. It was filtered, washed with toluene (2x10ml, 25-30°C) and dried at 55-60°C under reduced pressure (10-50 mm Hg).
Yield: 13.58g
Water content: 1.72%w/w (by F) EXAMPLE-9
PREPARATION OF 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRIFLUOROPHENYL)-BUTYL]- 5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-[l,2,4]-TRIAZOLO-[4,3- aJPYRAZINE CINNAMATE HEMIHYDRATE
Cinnamic acid (3.63g, 0.0245 moles) was added to a solution of Sitagliptin base (lOg, 0.0245mole) in 150 ml of ethyl acetate at 25-30°C. Thereafter, the contents were maintained at 25- 30°C for ~15hr. The solid was filtered, washed with ethyl acetate (2x10ml, 25-30°C) and dried at 55-60°C under reduced pressure (10-50 mm Hg).
Yield: 1 1.52g
Water content: 1.89%w/w (by KF) EXAMPLE-10
CRYSTALLIZATION OF 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRIFLUORO-PHENYL)-
BUTYL]-5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-[l,2,4]-TRIAZOLO-[4,3- a]PYRAZINE CINNAMATE HEMIHYDRATE IN ETHYL ACETATE
Sitagliptin cinnamate (lOg) was suspended in ethyl acetate (100ml) at 25-30°C. The slurry was heated to 75-77°C to obtain a clear solution. This solution was cooled to 25-30°C and stirred further for ~15hr at this temperature. The crystallized product was filtered, washed with ethyl acetate (2x10ml, 25-30°C) and dried at 55-60°C under reduced pressure (10-50 mm Hg).
Yield: 6.32g
Water content: 1.75%w/w (by KF) EXAMPLE-11
PREPARATION OF AMORPHOUS 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRI- FLUOROPHENYL)-BUTYL]-5,6,7,8-TETRAHYDRO-3-(TRIFLUORO-METHYL)-[l,2,4]- TRIAZOLO-[4,3-a]PYRAZINE CINNAMATE
Crystalline Sitagliptin cinnamate hemihydrate (5g) was dissolved in 650 ml of DM water at 25- 30°C. Thereafter, the contents were filtered and obtained filtrate was lyophilized to obtain amorphous Sitagliptin cinnamate, which is hygroscopic in nature.
Yield: 4.61 g
EXAMPLE-12
PREPARATION OF AMORPHOUS 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRI- FLUOROPHENYL)-BUTYL]-5,6,7,8-TETRAHYDRO-3-(TRIFLUORO-METHYL)-[l,2,4]- TRIAZOLO-[4,3-a]PYRAZINE FORMATE
Crystalline Sitagliptin formate (5g) was dissolved in 15 ml of DM water at 25-30°C. Thereafter, the contents were filtered and obtained filtrate was lyophilized to obtain amorphous Sitagliptin formate, which is hygroscopic in nature.
Yield: 4.72 g
EXAMPLE-13
PREPARATION OF 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRIFLUOROPHENYL)-BUTYL]- 5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-[l,2,4]-TRIAZOLO-[4,3- ajPYRAZINE NICOTINATE
Nicotinic acid (1.51g, 0.0122 moles) was added to preheated solution of Sitagliptin base (5g, 0.0245mole) in 75 ml of isopropyl alcohol at 65-70°C. Thereafter, the contents were heated to 70- 75°C and stirred at this temperature for lh. Obtained solution was concentrated at 40-45°C under reduced pressure to distill ~60 of isopropyl alcohol and cyclohexane (100ml) was added. Thereafter, precipitated product was stirred further for 5h at 25-30°C. Product was filtered, washed with cyclohexane (2x10ml, 25-30°C) and dried at 50-60°C under reduced pressure (10-50 mm Hg).
Yield: 7.1 1 g
Water content: 1.72 %w/w (by KF) EXAMPLE-14
PREPARATION OF 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRIFLUOROPHENYL)-BUTYL]- 5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-[l,2,4]-TRIAZOLO-[4,3- aJPYRAZINE PICOLINATE
Picolinic acid (1.5 lg, 0. 0.0122 moles) was added to preheated solution of Sitagliptin base (5g, 0.0122mole) in 75 ml of isopropyl alcohol at 65-70°C. Thereafter, the contents were heated to 70- 75°C and stirred at this temperature for l h. Obtained solution was cooled to 25-30°C and thereafter, precipitated product was stirred further for ~20h at this temperature. Product was filtered, washed with isopropyl alcohol (2x5ml, 25-30°C) and dried at 50-60°C under reduced pressure (10-50 mm Hg).
Yield: 6.28 g
Water content: 0.12%w/w (by KF) EXAMPLE-15
PREPARATION OF 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRIFLUOROPHENYL)-BUTYL]- 5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-[l,2,4]-TRIAZOLO-[4,3- aJPYRAZINE NITRATE
Nitric acid (60%w/w, 2.84g„ 0.0270 moles) was added to preheated solution of Sitagliptin base (l Og, 0.0245mole) in 100 ml of isopropyl alcohol at 50-60°C and contents were stirred at this temperature for 1 hr. Obtained solution was cooled to 25-30°C and thereafter, precipitated product was stirred further for ~2h at 25-30°C. Product was filtered, washed with isopropyl alcohol (2x10ml, 25-30°C) and dried at 45-50°C under reduced pressure (-20 mm Hg).
Yield: 9.90 g Water content: 0.28%w/w (by KF)
EXAMPLE-16
PREPARATION OF 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRIFLUOROPHENYL)-BUTYL]- 5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-[l,2,4]-TRIAZOLO-[4,3- a]PYRAZINE NITRATE HYDRATE
Nitric acid (60%w/w, 2.58g, 0.024 moles) was added to a suspension of Sitagliptin base (lOg, 0.0245mole) in 50 ml of DM water at 25-35°C. Isopropyl alcohol (10ml) was added and contents were stirred at this temperature for 1 hr. The resulting slurry mass was further cooled to 5-10°C and stirred further for ~l h at the same temperature. Product was filtered, washed with precooled DM water (2x10ml, 5-10°C) and dried at 45-50°C under reduced pressure (-20 mm Hg).
Yield: 9.50 g
Water content: 5.49%w/w (by KF) EXAMPLE-17
PREPARATION OF AMORPHOUS 7-[(3R)-3-AMINO-l-OXO-4-(2,4,5-TRI- FLUOROPHENYL)-BUTYL]-5,6,7,8 TETRAHYDRO-3-(TRIFLUOROMETHYL) -[1,2,4]- TRIAZOLO-[4,3-a]PYRAZINE NITRATE
Crystalline Sitagliptin nitrate (5g) was dissolved in 50 ml of DM water at 25-30°C. Thereafter, the contents were filtered and the filtrate was lyophilized to obtain amorphous Sitagliptin nitrate, which is hygroscopic in nature.
Yield: 4.8g

Claims

WE CLAIM:
1. Pharmaceutically acceptable salts of 7-[(3R)-3- amino- l-oxo-4-(2,4,5-trifluorophenyl) butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-[ 1 ,2,4]-triazolo[4,3-a]pyrazine of Formula I,
Figure imgf000019_0001
or solvates or hydrates thereof; wherein salt represents formate, picolinate, nicotinate, stearate, palmitate and laurate.
2. A process for the preparation of salts of Sitagliptin selected from formate, picolinate, nicotinate, stearate, palmitate and laurate, which comprises:
a) providing a mixture comprising Sitagliptin (base) and pharmaceutically acceptable acid selected from the group consisting of formic acid, picolinic acid, nicotinic acid, stearic acid, palmitic acid and lauric acid; and
b) isolating the corresponding acid addition salt of Sitagliptin.
3. Amorphous Sitagliptin salt, wherein salt is selected from formate, cinnamate, picolinate, nicotinate, stearate, palmitate, laurate and nitrate.
4. A process for the preparation of amorphous salts of Sitagliptin selected from formate, picolinate, nicotinate, stearate, palmitate, laurate and nitrate comprising:
a) dissolution of Sitagliptin salts in a solvent selected from water, alcohols and mixtures thereof; and
b) lyophilization.
5. Crystalline Sitagliptin salt, wherein salt is selected from formate, picolinate, nicotinate, stearate, palmitate and laurate.
6. Crystalline Form II of Sitagliptin nitrate having powder X-ray diffraction pattern comprising °2Θ values (±0.2) at 17.20, 18.48, 22.30, 23.42, 25.60.
7. A process for the preparation of crystalline Form II of Sitagliptin nitrate, which comprises: a) providing a mixture comprising Sitagliptin base and nitric acid in a solvent; and b) isolating the crystalline Form II of Sitagliptin nitrate
wherein solvent is water or isopropyl alcohol or mixture thereof.
8. Crystalline Sitagliptin formate having powder X-ray diffraction pattern comprising °2Θ values (±0.2) at 14.95, 15.88, 19.32, 19.71, 26.24.
9. Crystalline Sitagliptin picolinate having powder X-ray diffraction pattern comprising °2Θ values (±0.2) at 14.76, 16.72, 22.93, 26.51, 26.85.
10. Crystalline Sitagliptin cinnamate hemihydrate having powder X-ray diffraction pattern comprising °20 values (±0.2) at 5.96, 18.51, 19.63, 22.62, 23.71.
1 1. A process for the preparation of Sitagliptin cinnamate hemihydrate comprising:
a) addition of cinnamic acid to preheated solution of Sitagliptin base in solvent;
b) heating the solution;
c) cooling to precipitate product; and
d) isolating the product.
wherein solvent is selected from isopropyl alcohol, toluene and ethyl acetate.
12. Crystalline Sitagliptin stearate having powder X-ray diffraction °20 values (±0.2) at 18.99, 19.41 , 20.57, 22.93, 24.43.
13. Crystalline Sitagliptin palmitate having powder X-ray diffraction °2Θ values (±0.2) at 19.46, 19.90, 21.1 1, 23.40, 24.26.
14. Crystalline Sitagliptin laurate having powder X-ray diffraction °2Θ values (±0.2) at 15.80, 18.90, 21.62, 23.90, 24.59.
15. Crystalline Sitagliptin nicotinate having powder X-ray diffraction °20 values (±0.2) at 15.31 ,
16.73, 18.96, 22.57, 26.94.
PCT/IB2011/002982 2010-12-09 2011-12-07 Novel salts of dipeptidyl peptidase iv inhibitor WO2012076973A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3759/CHE/2010 2010-12-09
IN3759CH2010 2010-12-09

Publications (2)

Publication Number Publication Date
WO2012076973A2 true WO2012076973A2 (en) 2012-06-14
WO2012076973A3 WO2012076973A3 (en) 2012-08-02

Family

ID=45509547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/002982 WO2012076973A2 (en) 2010-12-09 2011-12-07 Novel salts of dipeptidyl peptidase iv inhibitor

Country Status (1)

Country Link
WO (1) WO2012076973A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012131005A1 (en) * 2011-03-29 2012-10-04 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition of sitagliptin
WO2013054364A3 (en) * 2011-10-14 2013-07-04 Laurus Labs Private Limited Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof
WO2015114657A2 (en) 2014-01-21 2015-08-06 Cadila Healthcare Limited Amorphous form of sitagliptin free base
CN105503883A (en) * 2015-12-30 2016-04-20 西安交通大学 Sitagliptin-nitrate hybrid as well as preparation method and application thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699871B2 (en) 2001-07-06 2004-03-02 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060287528A1 (en) 2003-09-02 2006-12-21 Wenslow Robert M Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US20070021430A1 (en) 2003-09-23 2007-01-25 Chen Alex M Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US7326708B2 (en) 2003-06-24 2008-02-05 Merck & Co., Inc. Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US20080227786A1 (en) 2004-01-16 2008-09-18 Ferlita Russell R Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor
WO2009085990A2 (en) 2007-12-20 2009-07-09 Dr. Reddy's Laboratories Limited Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
US20090221592A1 (en) 2005-07-25 2009-09-03 Ellison Martha E Dodecylsulfate Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
US7612072B2 (en) 2004-09-15 2009-11-03 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
WO2010000469A2 (en) 2008-07-03 2010-01-07 Ratiopharm Gmbh Crystalline salts of sitagliptin
WO2010012781A2 (en) 2008-07-29 2010-02-04 Medichem, S.A. New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
WO2010092090A2 (en) 2009-02-11 2010-08-19 Lek Pharmaceuticals D.D. Novel salts of sitagliptin
US20100249140A1 (en) 2009-03-30 2010-09-30 Teva Pharmaceutical Industries Ltd. Solid state forms of sitagliptin salts

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060213A2 (en) * 2009-11-12 2011-05-19 Dr. Reddy's Laboratories Ltd. Preparation of sitagliptin and salts thereof

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699871B2 (en) 2001-07-06 2004-03-02 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7326708B2 (en) 2003-06-24 2008-02-05 Merck & Co., Inc. Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US20060287528A1 (en) 2003-09-02 2006-12-21 Wenslow Robert M Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US20070021430A1 (en) 2003-09-23 2007-01-25 Chen Alex M Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US20080227786A1 (en) 2004-01-16 2008-09-18 Ferlita Russell R Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor
US7612072B2 (en) 2004-09-15 2009-11-03 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US20090221592A1 (en) 2005-07-25 2009-09-03 Ellison Martha E Dodecylsulfate Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
WO2009085990A2 (en) 2007-12-20 2009-07-09 Dr. Reddy's Laboratories Limited Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2010000469A2 (en) 2008-07-03 2010-01-07 Ratiopharm Gmbh Crystalline salts of sitagliptin
WO2010012781A2 (en) 2008-07-29 2010-02-04 Medichem, S.A. New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
WO2010092090A2 (en) 2009-02-11 2010-08-19 Lek Pharmaceuticals D.D. Novel salts of sitagliptin
US20100249140A1 (en) 2009-03-30 2010-09-30 Teva Pharmaceutical Industries Ltd. Solid state forms of sitagliptin salts

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012131005A1 (en) * 2011-03-29 2012-10-04 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition of sitagliptin
EA029539B1 (en) * 2011-03-29 2018-04-30 Крка, Товарна Здравил, Д.Д., Ново Место Pharmaceutical composition of sitagliptin
EA029539B8 (en) * 2011-03-29 2018-06-29 Крка, Товарна Здравил, Д.Д., Ново Место Pharmaceutical composition of sitagliptin
WO2013054364A3 (en) * 2011-10-14 2013-07-04 Laurus Labs Private Limited Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof
US9181256B2 (en) 2011-10-14 2015-11-10 Laurus Labs Private Ltd. Salts of sitagliptin, process for the preparation and pharmaceutical composition therefore
US9388113B2 (en) 2011-10-14 2016-07-12 Laurus Labs Private Limited Salts of sitagliptin, process from the preparation and pharmaceutical composition therefore
WO2015114657A2 (en) 2014-01-21 2015-08-06 Cadila Healthcare Limited Amorphous form of sitagliptin free base
CN105503883A (en) * 2015-12-30 2016-04-20 西安交通大学 Sitagliptin-nitrate hybrid as well as preparation method and application thereof

Also Published As

Publication number Publication date
WO2012076973A3 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
RU2519717C2 (en) Crystalline salts of sitagliptin
EP2324027B1 (en) New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
EP2417106B1 (en) Process for preparing pyrrolidinium salts
EP2218721A1 (en) Novel salts of sitagliptin
CA2803559A1 (en) Nilotinib salts and crystalline forms thereof
EP2247570B1 (en) Novel salts of o-desmethyl-venlafaxine
WO2012076973A2 (en) Novel salts of dipeptidyl peptidase iv inhibitor
WO2004104010A1 (en) Crystalline form of cefdinir
KR101688238B1 (en) Choline and Tromethamine Salt of Licofelone
EP3398946A1 (en) Salt of morpholine derivative and crystalline form thereof, as well as preparation method, pharmaceutical composition and use of the same
EP2594570A1 (en) Crystal of thienopyrimidine derivative
EP2726483A1 (en) Novel salts of sitagliptin
IE75695B1 (en) 3-[(5-methyl-2-furanyl)methyl]-N-(4-piperidinyl)-3H-imidazo [4,5-b]-pyridin-2-amine 2-hydroxy-1,2,3-propanetricarboxylate
CZ2003615A3 (en) Hydrochloride salt of 5- [4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
AU2010283928A1 (en) Forms of dexlansoprazole and processes for the preparation thereof
KR101653816B1 (en) Crystalline Form of Sarpogrelate Oxalate Monohydrate or Sarpogrelate Oxalate Anhydride
KR20170134019A (en) Novel 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine(Linagliptin) ferulic acid salt and process for the preparation thereof
CN117396481A (en) Salts of PI3K delta inhibitors, crystalline forms thereof, methods of preparation and uses
WO2022224269A1 (en) Co-crystals, salts and solid forms of niraparib
WO2006099452A1 (en) Anhydrous ziprasidone mesylate and a process for its preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11811119

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11811119

Country of ref document: EP

Kind code of ref document: A2